http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111607571-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10051 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate | 2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111607571-B |
| titleOfInvention | A replicative oncolytic adenovirus that specifically activates immune co-stimulatory pathway and its preparation method and application |
| abstract | The invention relates to the field of biopharmaceuticals and tumor biotherapy, in particular to a replicative oncolytic adenovirus AD5 sCD137L and its application. The present invention discloses a design and construction method of a new type of replication oncolytic adenovirus AD5 sCD137L, and successfully obtained a new type of replication type oncolytic adenovirus AD5 sCD137L, which can selectively replicate in tumor cells and can be highly The soluble protein sCD137L is expressed, which can be secreted into the extracellular tumor microenvironment to activate the co-stimulatory signal receptor CD137 of the infiltrating lymphocytes recruited by the virus to exert biological functions. Experiments show that the novel replicative oncolytic adenovirus AD5 sCD137L of the present invention has strong anti-tumor immune activation, significant anti-tumor activity and safety, and has a very high prospect and value for developing anti-tumor drugs. |
| priorityDate | 2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 196.